Management of portal hypertension

Journal of Clinical Gastroenterology

Volumn 39, Issue 3, 2005, Pages 232-236

  Nietsch, Hubert H ^a,b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b NONE   (Germany)

Author keywords

Ascites; Hepatorenal syndrome; Management; Portal hypertension; Varices

Indexed keywords

ANTIBIOTIC AGENT; LACTULOSE; MIDODRINE; NEOMYCIN; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; SOMATOSTATIN; SPIRONOLACTONE; TERLIPRESSIN;

ANTIBIOTIC PROPHYLAXIS; ASCITES; BLEEDING; BRAIN DISEASE; DIURETIC THERAPY; HEMODIALYSIS; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PARACENTESIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; SCLEROTHERAPY; SHUNTING; UREMIA; VARIX BLEEDING;

ACUTE DISEASE; ASCITES; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERTENSION, PORTAL;

EID: 14144251526     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000152783.22266.35     Document Type: Review

References (70)

1. Armonis A, Patch D, Burroughs A. Hepatic venous pressure measurement: an old test as a new prognostic marker in cirrhosis? Hepatology. 1997;25:245-248.
2. Bosch J, Pizcueta P, Feu F, et al. Pathophysiology of portal hypertension. Gastroenterol Clin North Am. 1992;21:1-14.
3. Shibayama Y, Nakata K. Localisation of increased hepatic vascular resistance in liver cirrhosis. Hepatology. 1985;5:643-647.
4. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology. 1996;24:233-240.
5. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology. 2002;35:478-491.
6. García-Pagán JC, Bosch J, Rodés J. The role of vasoactive mediators in portal hypertension. Semin Liver Dis. 1995;6:1-9.
7. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology. 1995;22:332-354.
8. Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet. 1995;346:1056-1059.
9. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med. 1988;319:983-989.
10. Beppu K, Inokuchi K, Koyanagi N, et al. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc. 1981;27:213-218.
11. Spiegel B, Targownik L, Dulai GS, et al. Endoscopic screening for esophageal varices in cirrhosis: is it ever cost effective? Hepatology. 2003;37:366-377.
12. Gimson AE, Westaby D, Hegarty J, et al. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology. 1986;6:410-413.
13. Feu F, Ruiz del Arbol L, Banares R, et al. J. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage: Variceal Bleeding Study Group. Gastroenterology. 1996; 111:1291-1299.
14. Pedretti G, Elia G, Calzetti C, et al. Octreotide versus terlipressin in acute variceal hemorrhage in liver cirrhosis: emergency control and prevention of early rebleeding. Clin Invest. 1994;72:653-659.
15. Escorsell A, Ruiz del Arbol L, Planas R, et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology. 2000;32:471-476.
16. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev. 2001;1:CD002147.
17. Bernard B, Grange JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29:1655-1661.
18. Paquet KJ, Feussner H. Endoscopic sclerosis and esophageal balloon tamponade in acute hemorrhage from esophagogastric varices: a prospective controlled randomized trial. Hepatology. 1985;5:580-583.
19. Helmy A, Hayes PC. Review article: current endoscopic therapeutic options in the management of variceal bleeding. Aliment Pharmacol Ther. 2001;15:575-594.
20. Van Stiegmann G, Cambre T, Sun JH. A new endoscopic elastic band ligating device. Gastrointest Endosc. 1986;32:230-233.
21. Gross M, Schiemann U, Muhlhofer A, et al. Meta-analysis: efficacy of therapeutic regimens in ongoing variceal bleeding. Endoscopy. 2001;33: 737-746.
22. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta-analysis. Ann Intern Med. 1995;123:280-287.
23. Vlavianos P, Gimson AES, Westaby D, et al. Ballon tamponade in variceal bleeding: use and misuse. Br Med J. 1989;298:1158-1165.
24. Chau TN, Patch D, Chan YW, et al. 'Salvage' transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology. 1998;114:981-987.
25. McCormick PA, Dick R, Panagou EB, et al. Emergency transjugular intrahepatic portosystemic stent shunting as salvage treatment for uncontrolled variceal bleeding. Br J Surg. 1994;81:1324-1327.
26. Rikkers LF, Sorrell WT, Jin G. Which portosystemic shunt is best? Gastroenterol Clin North Am. 1992;21:179-196.
27. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 2000;33:846-852.
28. Grace ND. Practice guidelines: diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol. 1997;92: 1081-1091.
29. Lebrec D, Hillon P, Munoz C, et al. The effect of propanolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology. 1982;2:523-527.
30. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19:475-505.
31. Deleted in proof.
32. Thalheimer U, Mela M, Patch D, et al. Targeting portal pressure measurements: a critical reappraisal. Hepatology. 2004;39:286-290.
33. Garcia-Pagan JC, Escorsell A, Moitinho E, et al. Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Semin Liver Dis. 1999;19:427-438.
34. Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacologic treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37:902-908.
35. Pare P, Talbot J, Hoefs JC. Serum-ascites albumin concentration gradient: a physiologic approach to the differential diagnosis of ascites. Gastroenterology. 1983;85:240-244.
36. Ginès P, Arroyo V, Rodés J. Pharmacotherapy of ascites associated with cirrhosis. Drugs. 1992;43:316-332.
37. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology. 1998;27:264-272.
38. Gerbes AL. Medical treatment of ascites in cirrhosis. J Hepatol. 1993;17 (suppl 2):4-9.
39. Gines P, Arroyo V, Rodes J. Pathophysiology, complications, and treatment of ascites. Clin Liver Dis. 1997;1:129-155.
40. Salerno F, Merli M, Cazzaniga M, et al. MELD score is better than Child-Pugh score in predicting 3-months survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol. 2002;36:494-500.
41. Boyer TD. Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology. 2003;124:1700-1710.
42. Rossle M, Siegerstetter V, Huber M, et al. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. Liver. 1998;18:73-89.
43. Rosch J, Keller FS. Transjugular intrahepatic portosystemic shunt: present status, comparison with endoscopic therapy and shunt surgery, and future perspectives. World J Surg. 2001;25:337-345.
44. Saxon RS, Ross PL, Mendel-Hartvig J, et al. Transjugular intrahepatic portosystemic shunt patency and the importance of stenosis location in the development of recurrent symptoms. Radiology. 1998;207:683-693.
45. Rossi P, Salvatori FM, Fanelli F, et al. Polytetrafluoroethylene-covered Nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. Radiology. 2004;231:820-830.
46. Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology. 1993; 105:229-236.
47. Ginès P, Guevera M, Arroyo V, et al. Hepatorenal syndrome. Lancet. 2003;362:1819-1827.
48. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis: International Ascites Club. Hepatology. 1996;23:164-176.
49. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994;20:1495-1501.
50. Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94:1493-1502.
51. Cardenas A, Gines P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology. 2001;34:671-676.
52. Pham PT, Pham PC, Wilkinson AH. The kidney in liver transplantation. Clin Liver Dis. 2000;4:567-590.
53. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36:941-948.
54. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923-930.
55. Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology. 1998;28:416-422.
56. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000;47:288-295.
57. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716-721.
58. Schafer DF, Jones EA. Hepatic encephalopathy and the gamma-aminobutyric- acid neurotransmitter system. Lancet. 1982;1:18.
59. Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis. 2002;17:221-227.
60. James JH, Zipparo V, Jeppson B, et al. Hyperammonemia, plasma amino acid imbalance and blood-brain amino acid transport: a unified theory of portal-systemic encephalopathy. Lancet. 1979;2:772.
61. Michalak A, Rose C, Butterworth J, et al. Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure. Hepatology. 1996;24:908.
62. Ferenci P, Püspök A, Steindl P. Current concepts in the pathophysiology of hepatic encephalopathy. Eur J Clin Invest. 1992;22:573.
63. Ferenci P, Herneth A, Steindl P. Newer approaches to treatment of hepatic encephalopathy. Semin Liver Dis. 1996;16:329.
64. Als-Nielsen B, Gluud L, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev. 2004;2:CD003044.
65. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. Gastroenterology. 1977;72:573.
66. Uribe M, Campollo O, Vargas F. Acidifying enemas (lactitol and lactulose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind randomized clinical trial. Hepatology. 1987;7:639.
67. Als-Nielsen B, Kjaergard LL, Gluud C. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy (Cochrane Review). Cochrane Database Syst Rev. 2001;4:CD002798.
68. Goulenok C, Bernard B, Cadranel JF, et al. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther. 2002;16:361.
69. Mitzner S, Loock J, Peszynski P, et al. Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS: a review of clinical, biochemical, and electrophysiological data. Metab Brain Dis. 2002;17:463-475.
70. Stange J, Mitzner SR, Klammt S, et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl. 2000;6:603-613.